DNA methylation-based classification of sinonasal undifferentiated carcinoma

[1]  R. Pramanik,et al.  SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns. , 2019, Human pathology.

[2]  C. Creighton,et al.  Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny. , 2018, Cell reports.

[3]  Laura H. Tang,et al.  The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma , 2018, Modern Pathology.

[4]  Y. Ning,et al.  Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. , 2018, The American journal of surgical pathology.

[5]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[6]  A. Ghazalpour,et al.  Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas , 2018, PloS one.

[7]  A. Chinnaiyan,et al.  Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications , 2017, Molecular Cancer Research.

[8]  Simion I. Chiosea,et al.  Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas , 2017, The Journal of pathology.

[9]  P. Stephens,et al.  Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. , 2017, The oncologist.

[10]  M. Ladanyi,et al.  DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. , 2017, JCO precision oncology.

[11]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[12]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[13]  Simion I. Chiosea,et al.  SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity , 2017, The American journal of surgical pathology.

[14]  J. Hornick,et al.  Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma , 2017, Modern Pathology.

[15]  Julie M. Batten,et al.  IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. , 2016, Cancer research.

[16]  J. Bishop,et al.  Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status , 2016, The American journal of surgical pathology.

[17]  R. Weber,et al.  Neuroendocrine neoplasms of the sinonasal region , 2016, Head & neck.

[18]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[19]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[20]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[21]  K. Magliocca,et al.  Retrospective analysis of nuclear protein in testis (NUT) midline carcinoma in the upper aerodigestive tract and mediastinum. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[22]  E. Hanna,et al.  Esthesioneuroblastoma, Neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma: Differentiation in Diagnosis and Treatment , 2014, International Archives of Otorhinolaryngology.

[23]  C. Antonescu,et al.  SMARCB1 (INI-1)-deficient Carcinomas of the Sinonasal Tract , 2014, The American journal of surgical pathology.

[24]  H. Iro,et al.  SMARCB1(INI1)-deficient Sinonasal Basaloid Carcinoma , 2014, The American journal of surgical pathology.

[25]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[26]  J. Bishop,et al.  NUT Midline Carcinomas of the Sinonasal Tract , 2012, The American journal of surgical pathology.

[27]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[28]  W. Chan,et al.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[29]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[30]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[31]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[32]  S. Mills,et al.  A Histologic and Immunohistochemical Study Describing the Diversity of Tumors Classified as Sinonasal High-grade Nonintestinal Adenocarcinomas , 2011, The American journal of surgical pathology.

[33]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[34]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[35]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[36]  E. Babin,et al.  Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses , 2006, The Journal of Laryngology & Otology.

[37]  S. Mills,et al.  "Undifferentiated" small round cell tumors of the sinonasal tract: differential diagnosis update. , 2005, American journal of clinical pathology.

[38]  L. Fabbri,et al.  Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung , 2005 .

[39]  A. Ejaz,et al.  Sinonasal Undifferentiated Carcinoma: Clinical and Pathologic Features and a Discussion on Classification, Cellular Differentiation, and Differential Diagnosis , 2005, Advances in anatomic pathology.

[40]  G. Fuller,et al.  Misdiagnosis of olfactory neuroblastoma. , 2002, Neurosurgical focus.

[41]  A. Huvos,et al.  Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. , 1998, Human pathology.

[42]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[43]  H. Frierson,et al.  Sinonasal Undifferentiated Carcinoma: An Aggressive Neoplasm Derived from Schneiderian Epithelium and Distinct from Olfactory Neuroblastoma , 1986, The American journal of surgical pathology.

[44]  J. Bishop,et al.  INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.

[45]  David T. W. Jones,et al.  DNA methylation-based reclassification of olfactory neuroblastoma , 2018, Acta Neuropathologica.

[46]  M. Snuderl,et al.  Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. , 2018, Methods in molecular biology.

[47]  A. Franchi.  Nasal Cavity, Paranasal Sinuses, and Nasopharynx , 2016 .

[48]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[49]  B. Wenig,et al.  CHAPTER 10 – Nasal Cavity, Paranasal Sinuses, and Nasopharynx , 2009 .

[50]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .